Literature DB >> 27893122

Cost-effectiveness of PCSK9 Inhibitor Therapy.

Vera Mastey1, Bryan M Johnstone2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27893122     DOI： 10.1001/jama.2016.16286

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

1.  Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.

Authors:  Ann Marie Navar; Benjamin Taylor; Hillary Mulder; Eugene Fievitz; Keri L Monda; Anna Fievitz; Juan F Maya; J Antonio G López; Eric D Peterson
Journal:  JAMA Cardiol       Date:  2017-11-01       Impact factor: 14.676

2.  Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.

Authors:  Jennifer A Rymer; Katherine E Mues; Keri L Monda; Emily W Bratton; Heidi S Wirtz; Ted Okerson; Robert A Overman; M Alan Brookhart; Paul Muntner; Tracy Y Wang
Journal:  J Am Heart Assoc       Date:  2020-04-24       Impact factor: 5.501
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.